Thursday, February 2, 2023
wellness India Expo
Home Tags MRNA

Tag: mRNA

Cipla & Ethris partner for the development of mRNA-based therapies

The definitive agreements for equity investment of EUR 15 million in Ethris GmbH will fast-track Cipla’s participation in the mRNA space

BioVoice eMagazine December 2022 Issue 3 Volume 3

Click to Read: BioVoice eMagazine December 2022 Issue 3 Volume 3 The Cover Story in the current edition focuses on India's strong biotech R&D segment...

Study unveils protein synthesis in red blood cells

A research team led by Sandeep M Eswarappa, Associate Professor, Department of Biochemistry, Indian Institute of Science, Bengaluru, has identified that mature human RBCs can also make their proteins

CEPI and SK bioscience partner to advance mRNA vaccine technology

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus

Japan’s homegrown COVID-19 mRNA vaccine needs superior safety & efficacy data...

In 2021, leading mRNA vaccines, Comirnaty and Spikevax, generated combined sales of more than $54 billion globally and are expected to generate similar or greater sales in 2022

Pfizer initiates Phase 3 Study of mRNA-based Influenza vaccine

First Phase 3 efficacy study to be conducted using an mRNA-based influenza vaccine; study will enroll 25,000 U.S. adults 18 years and older

Moderna seeks US-FDA approval for emergency use of BA.4/BA.5 Omicron booster

Subject to the regulatory approval, Moderna is ready to ship bivalent booster mRNA-1273.222 in September

Post DCGI approval, Gennova to produce 40-50 lakh doses of GEMCOVAC-19...

To be sold under the brand name GEMCOVAC™-19, the two dose vaccine will be available for adults above 18 years of age and administered intramuscularly at 28 days apart

CCMB develops India’s first mRNA based Covid-19 vaccine candidate

The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere

Moderna kickstarts Phase 1/2 study for influenza vaccine candidate

Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle